Anal, Colon, and Rectal Cancers
3
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
6 treatments under study, led by Autologous Hematopoietic And Immune Cell Rescue Transplantation
Related Conditions
Often studied with 19 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
1 terminated out of 3 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Research Network
Common Treatments
- Autologous Hematopoietic And Immune Cell Rescue Transplantation1
- Vandetanib1
- Autologous Tumor Cell Cpg Vaccine1
- Bevacizumab1
- Capecitabine1
Active Sponsors
- Stanford University2
- AstraZeneca1
- Branimir Sikic1
Top Investigators
Stanford University
Stanford University
Stanford University
Related Conditions
- Colorectal Neoplasms3
- Colonrectal Cancer2
- Lung Cancer Small Cell Lung Cancer Sclc1
- Lung Cancer Nonsmall Cell Cancer Nsclc1
- Head And Neck Cancers Oral Cavity1